236 related articles for article (PubMed ID: 27178681)
21. Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Kim R; Chabot J; Saif MW
JOP; 2011 Jul; 12(4):362-3. PubMed ID: 21737897
[TBL] [Abstract][Full Text] [Related]
22. [Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Auvray M; Baylot C; Blanc-Durand F; Borcoman E; Pons-Tostivint E; Vignot S
Bull Cancer; 2018 Nov; 105(11):1084-1093. PubMed ID: 30340752
[TBL] [Abstract][Full Text] [Related]
23. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.
Massey PR; Wang R; Prasad V; Bates SE; Fojo T
Oncologist; 2016 Mar; 21(3):261-8. PubMed ID: 26888691
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merika E; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with failure to publish large randomized trials presented at an oncology meeting.
Krzyzanowska MK; Pintilie M; Tannock IF
JAMA; 2003 Jul; 290(4):495-501. PubMed ID: 12876092
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Hsu C; Saif MW
JOP; 2011 Jul; 12(4):330-3. PubMed ID: 21737889
[TBL] [Abstract][Full Text] [Related]
27. [2015 through the eyes of the Bulletin of Cancer editorial board].
Magné N; Massard C; Bay JO; André T; Blay JY; Goncalves A; Orbach D; Wislez M; Thariat J; Penel N; Rancoule C; Vignot S
Bull Cancer; 2016 Jan; 103(1):3-17. PubMed ID: 26782079
[TBL] [Abstract][Full Text] [Related]
28. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Alsamarai S; Libutti SK; Saif MW
JOP; 2010 Jul; 11(4):336-40. PubMed ID: 20601807
[TBL] [Abstract][Full Text] [Related]
29. Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting.
Krzyzanowska MK; Pintilie M; Brezden-Masley C; Dent R; Tannock IF
J Clin Oncol; 2004 May; 22(10):1993-9. PubMed ID: 15143092
[TBL] [Abstract][Full Text] [Related]
30. 2007 EORTC-NCI-ASCO annual meeting: molecular markers in cancer.
Lukan C
Ecancermedicalscience; 2008; 2():75. PubMed ID: 22275966
[TBL] [Abstract][Full Text] [Related]
31. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting.
Moy B; Bradbury AR; Helft PR; Egleston BL; Sheikh-Salah M; Peppercorn J
J Clin Oncol; 2013 Jul; 31(21):2678-84. PubMed ID: 23775973
[TBL] [Abstract][Full Text] [Related]
32. Transition from meeting abstract to full-length journal article for randomized controlled trials.
Toma M; McAlister FA; Bialy L; Adams D; Vandermeer B; Armstrong PW
JAMA; 2006 Mar; 295(11):1281-7. PubMed ID: 16537738
[TBL] [Abstract][Full Text] [Related]
33. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Brus C; Saif MW
JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
[TBL] [Abstract][Full Text] [Related]
34. Representation of women plenary speakers at the American Academy of Neurology Annual Meeting.
Singhal D; Bank AM; Poorman JA; Doshi TL; Parekh R; Parangi S; Hopf HW; Chandrabose R; Larson AR; Silver JK
Neurology; 2020 Dec; 95(22):e3045-e3059. PubMed ID: 33109622
[TBL] [Abstract][Full Text] [Related]
35. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
36. Publication outcomes of phase II oncology clinical trials.
Hoeg RT; Lee JA; Mathiason MA; Rokkones K; Serck SL; Crampton KL; Emmel AE; Severson EA; Go RS
Am J Clin Oncol; 2009 Jun; 32(3):253-7. PubMed ID: 19349853
[TBL] [Abstract][Full Text] [Related]
37. ASCO 2007: plenary top 5.
Oncology (Williston Park); 2007 Jun; 21(7):896. PubMed ID: 17722746
[No Abstract] [Full Text] [Related]
38. Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research.
Hampson LA; Joffe S; Fowler R; Verter J; Emanuel EJ
J Clin Oncol; 2007 Aug; 25(24):3609-14. PubMed ID: 17704409
[TBL] [Abstract][Full Text] [Related]
39. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
Schrag D; Garewal HS; Burstein HJ; Samson DJ; Von Hoff DD; Somerfield MR;
J Clin Oncol; 2004 Sep; 22(17):3631-8. PubMed ID: 15289488
[TBL] [Abstract][Full Text] [Related]
40. Society of Gynecologic Investigation: what gets published?
Gandhi SG; Gilbert WM
J Soc Gynecol Investig; 2004 Dec; 11(8):562-5. PubMed ID: 15582502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
